These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38669792)

  • 21. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1.
    Nanri D; Yuge K; Goto K; Kimura T; Yae Y; Mizuochi T; Sato R; Itonaga T; Maeda T; Yamashita Y
    Kurume Med J; 2024 May; 69(3.4):255-259. PubMed ID: 38233181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
    Bitetti I; Lanzara V; Margiotta G; Varone A
    Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
    Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
    Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.
    Funato M; Kino A; Iwata R; Yumioka M; Yamashita K; Urui C; Uno R; Kondo E; Morioka E; Ogawa Y; Kawamura A; Kusukawa T; Minatsu H
    Brain Dev; 2024 Jan; 46(1):62-67. PubMed ID: 37657961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy.
    Wiedmann L; Cairns J
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):469-482. PubMed ID: 36947403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia.
    Wang T; Scuffham P; Byrnes J; Downes M
    J Neurol; 2022 Dec; 269(12):6544-6554. PubMed ID: 35980467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential treatment with nusinersen, Zolgensma
    Bitetti I; Manna MR; Stella R; Varone A
    Acta Myol; 2023; 42(2-3):82-85. PubMed ID: 38090542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selecting disease-modifying medications in 5q spinal muscular atrophy.
    Cartwright MS; Upadhya S
    Muscle Nerve; 2021 Oct; 64(4):404-412. PubMed ID: 34231920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
    Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Servais L; Xiong H; Zanoteli E; Baranello G; Bruno C; Day JW; Deconinck N; Klein A; Mercuri E; Vlodavets D; Wang Y; Dodman A; El-Khairi M; Gorni K; Jaber B; Kletzl H; Gaki E; Fontoura P; Darras BT;
    Lancet Neurol; 2022 Dec; 21(12):1110-1119. PubMed ID: 36244364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports.
    Mizuno T; Kanouchi T; Tamura Y; Hirata K; Emoto R; Suzuki T; Kashimada K; Morio T
    BMC Neurol; 2023 Oct; 23(1):392. PubMed ID: 37907848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the Therapy of Spinal Muscular Atrophy.
    Klotz J; Tesi Rocha C; Dunaway Young S; Duong T; Buu M; Sampson J; Day JW
    J Pediatr; 2021 Sep; 236():13-20.e1. PubMed ID: 34197889
    [No Abstract]   [Full Text] [Related]  

  • 33. Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec.
    Leon-Astudillo C; Wagner M; Salabarria SM; Lammers J; Berthy J; Zingariello CD; Byrne BJ; Smith BK
    Sleep Med; 2023 Jan; 101():234-237. PubMed ID: 36442421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment.
    Brakemeier S; Lipka J; Schlag M; Kleinschnitz C; Hagenacker T
    J Neurol; 2024 May; 271(5):2649-2657. PubMed ID: 38358553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective.
    Connock M; Andronis L; Auguste P; Dussart C; Armoiry X
    Expert Opin Biol Ther; 2020 Jul; 20(7):823-827. PubMed ID: 32434404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical perspectives: Treating spinal muscular atrophy.
    McPheron MA; Felker MV
    Mol Ther; 2024 Jun; ():. PubMed ID: 38894541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experience of the treatment of spinal muscular atrophy type 3 Kugelberg-Welander with Nusinersen].
    Shchepankevich LA; Ushkalenko VK; Dolotov KA; Maksimova YV; Veretelnikov IA; Taneeva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4):153-158. PubMed ID: 38676690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study.
    Chiriboga CA; Bruno C; Duong T; Fischer D; Mercuri E; Kirschner J; Kostera-Pruszczyk A; Jaber B; Gorni K; Kletzl H; Carruthers I; Martin C; Warren F; Scalco RS; Wagner KR; Muntoni F;
    Neurol Ther; 2023 Apr; 12(2):543-557. PubMed ID: 36780114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments.
    Salort-Campana E; Solé G; Magot A; Tard C; Noury JB; Behin A; De La Cruz E; Boyer F; Lefeuvre C; Masingue M; Debergé L; Finet A; Brison M; Spinazzi M; Pegat A; Sacconi S; Malfatti E; Choumert A; Bellance R; Bedat-Millet AL; Feasson L; Vuillerot C; Jacquin-Piques A; Michaud M; Pereon Y; Stojkovic T; Laforêt P; Attarian S; Cintas P
    Orphanet J Rare Dis; 2024 Jan; 19(1):24. PubMed ID: 38268028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Qiao Y; Chi Y; Gu J; Ma Y
    Brain Sci; 2023 Oct; 13(10):. PubMed ID: 37891788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.